Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Next Previous
X
Search
Trial Profile

An International, Multicenter, Open-label Study to Evaluate Safety, Tolerability, Biodistribution, Dosimetry and Preliminary Efficacy of 177Lu-OPS201 for the Therapy of Somatostatin Receptor-positive Neuroendocrine Tumors (NETs)

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 28 Jun 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutetium 177 satoreotide tetraxetan (Primary)
  • Indications Carcinoid tumour; Gastrointestinal cancer; Lung cancer; Neuroendocrine tumours; Pancreatic cancer; Paraganglioma; Phaeochromocytoma
  • Focus Adverse reactions
  • Sponsors Ipsen

    • Most Recent Events

    • 27 Jun 2024 Results evaluating the dosimetry and pharmacokinetics of the novel radiolabelled somatostatin receptor antagonist [177Lu]Lu-satoreotide tetraxetan in patients with advanced neuroendocrine tumours , published in the European Journal of Nuclear Medicine and Molecular Imaging
    • 01 Dec 2023 Results assessing safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours, published in the European Journal of Nuclear Medicine and Molecular Imaging.
    • 28 Sep 2023 According to an Ariceum Therapeutics Media Release, results of this study published in he European Journal of Nuclear Medicine and Molecular Imaging.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top